Gujarat Themis Biosyn (GTBL) acquired Sanofi's portfolio of 13 anti-TB and anti-infective brands for €158 million cash.

This move strengthens GTBL's global generics platform and expands its international footprint across 55+ countries, leveraging existing API capabilities.